When every respondent in a survey agrees, it’s more than a trend; it’s a mandate. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, all participants agreed that real-world evidence (RWE) has the potential to improve regulatory submissions....
As 2025 wraps up, the TriNetX team is reflecting on a year of milestones, among them, being named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies list this November. Earlier this year, TriNetX was also recognized among the Top 25...
Chimeric antigen receptor (CAR) T-cell therapy is among the most promising breakthroughs in modern oncology. By genetically engineering a patient’s T lymphocytes to recognize and destroy cancer cells, CAR T-cell therapy has redefined what is possible in adoptive...
The data and insights highlighted are drawn from the Biotech Playbook for Progress, a comprehensive resource built from a 2025 TriNetX survey of 150 biotech and pharma executives. Biotech has always been a high-wire act: big science balanced on limited resources. But...
The recent ISPOR Europe 2025 conference, held under the inspiring theme ‘Powering Value and Access Through Patient-Centered Collaboration,’ featured a dedicated track on patient-centered research that underscored ISPOR’s commitment to embedding patient voices at the...
I recently had the opportunity to sit down with Danny Levine for an episode of his RARECast podcast to discuss something I’m deeply passionate about: how real-world data (RWD) is transforming the landscape of rare disease research. As someone who has spent my...
Access to real-world data (RWD) is no longer the challenge; our ability to interact with it is. The barrier lies in the friction between researchers and the systems designed to unlock RWD’s potential. Unless we remove that friction, the promise of faster, smarter,...
When we think about the future of clinical research, it’s easy to picture gleaming technology, seamless data flows, and a world where trials are faster, smarter, and more inclusive. But let’s be honest. We’re not there yet. That’s exactly the conversation I had in...
The clinical trial industry faces a persistent and costly challenge: poor site selection. With up to 85% of trials failing to meet enrollment targets due in part to suboptimal site identification, the path from promising therapeutic concept to patient access remains...
In today’s era of exponential data growth, real-world data (RWD) is abundant, but its value hinges on our ability to interpret it with speed, scale, and precision. That’s where artificial intelligence (AI) comes into play. At TriNetX, we’re seeing firsthand how the...
